E08.3599 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye

Name of the Condition

• Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye

Summary

This condition involves diabetes mellitus resulting from an underlying health issue, accompanied by proliferative diabetic retinopathy without macular edema in an unspecified eye. Proliferative diabetic retinopathy is an advanced stage of retinal damage caused by prolonged high blood sugar, characterized by the growth of abnormal blood vessels on the retina. The absence of macular edema means the central part of the retina (macula) is not swollen, though the abnormal vessel growth still poses a risk of vision impairment if unmanaged. The unspecified eye designation indicates the condition may affect one or both eyes, or the specific eye is not documented.

Causes

The condition arises when an underlying disease impairs insulin production or function, leading to secondary diabetes. Examples of such underlying conditions include pancreatic disorders, hormonal imbalances, or genetic syndromes. Persistent hyperglycemia from this secondary diabetes damages retinal blood vessels, triggering proliferative changes. The lack of macular edema suggests the retinal damage has not yet caused fluid accumulation in the macula, and the unspecified eye designation indicates the condition may be unilateral or bilateral without specific documentation.

Risk Factors

• Having a medical condition known to cause secondary diabetes.
• Long-standing uncontrolled blood sugar levels.
• High blood pressure and elevated cholesterol.
• Smoking and obesity.
• Advanced age.

Symptoms

• Blurred or distorted vision.
• Floaters or spots in the visual field.
• Difficulty seeing at night.
• Sudden vision loss (in severe cases).
• Reduced visual acuity.

Diagnosis

Diagnosis involves a comprehensive eye examination, including dilated retinal imaging (e.g., fundus photography or optical coherence tomography) to assess retinal blood vessel changes. Blood tests to confirm hyperglycemia and identify the underlying condition causing secondary diabetes are also performed. The absence of macular edema is confirmed through retinal imaging, and the unspecified eye designation is noted if the condition affects one or both eyes without specific documentation.

Treatment Options

• Blood sugar control: Tight glycemic management to slow retinal damage progression.
• Blood pressure and cholesterol management: Medications to reduce cardiovascular risk.
• Laser therapy: Photocoagulation to shrink abnormal retinal blood vessels.
• Anti-VEGF injections: To inhibit abnormal blood vessel growth (if needed).
• Regular monitoring: Ophthalmologic follow-up to track retinal changes.

Prognosis and Follow-Up

Prognosis depends on the underlying condition, blood sugar control, and timely treatment. With proper management, vision loss may be prevented or slowed. Follow-up includes regular eye exams (every 3–6 months) and ongoing monitoring of the underlying condition. Unmanaged proliferative retinopathy can lead to severe vision impairment or blindness.

Complications

• Vision loss or blindness.
• Retinal detachment.
• Glaucoma.
• Recurrent bleeding in the eye.

Lifestyle & Prevention

• Maintain stable blood sugar levels through diet, exercise, and medication.
• Control blood pressure and cholesterol.
• Avoid smoking.
• Regular eye screenings for early detection.
• Manage the underlying condition causing secondary diabetes.

When to Seek Professional Help

Seek immediate care if you experience sudden vision changes, floaters, or vision loss. Regular ophthalmologic evaluations are recommended for those with diabetes or secondary diabetes to monitor retinal health.

Tips for Medical Coders

Document the underlying condition causing secondary diabetes and specify if the proliferative diabetic retinopathy affects one or both eyes when known. Use this code when macular edema is absent and the eye is not specified. Ensure clinical documentation supports the absence of macular edema and the unspecified eye designation.